These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16949470

  • 1. Recent advances in erythropoietic agents in renal anemia.
    Macdougall IC.
    Semin Nephrol; 2006 Jul; 26(4):313-8. PubMed ID: 16949470
    [Abstract] [Full Text] [Related]

  • 2. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC.
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
    McGahan L.
    Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
    [Abstract] [Full Text] [Related]

  • 6. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
    Schmidt RJ.
    Expert Opin Pharmacother; 2009 Jun; 10(9):1509-14. PubMed ID: 19505218
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
    Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW.
    Exp Hematol; 2006 Oct; 34(10):1303-11. PubMed ID: 16982323
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Erythropoietin and renal failure.
    Macdougall IC.
    Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389
    [Abstract] [Full Text] [Related]

  • 11. Erythropoietic agents and the elderly.
    Agarwal N, Prchal JT.
    Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.